CXCR5 and leukemia: To study the anti-leukemia efficacy in a therapeutic approach, we transferred 2 × 106Eμ-Tcl1 cells, followed by a sublethal irradiation on day 7 and the administration of 2 × 106 CXCR5 or SP6 CAR-T cells on day 8 (Fig. 9f).